Chemomab Therapeutics (CMMB) Common Equity (2017 - 2025)
Chemomab Therapeutics' (CMMB) quarterly Common Equity came in at $12.3 million in Q4 2025, down 8.89% YoY from $13.5 million in Q4 2024, and up 9.82% on a QoQ basis from $11.2 million in Q3 2025.
Chemomab Therapeutics (CMMB) Common Equity (2017 - 2025) Analysis & Trends
Chemomab Therapeutics (CMMB) has 9 years of Common Equity data on file, last reported at $12.3 million in Q4 2025.
- Quarterly Common Equity fell 8.89% year-over-year to $12.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $12.3 million (down 8.89% YoY) and the FY2025 annual result came in at $12.3 million, down 8.89% from the prior year.
- Common Equity rose to $12.3 million in Q4 2025, from $11.2 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $68.0 million in Q2 2021 to a low of $9.7 million in Q2 2025.
- A 5-year average of $31.1 million and a median of $20.0 million in 2023 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2021 — Common Equity jumped 469.02% — and 2023, when it slumped 59.57%.
- Tracing CMMB's Common Equity over 5 years: stood at $61.5 million in 2021, then plunged by 41.07% to $36.2 million in 2022, then slumped by 53.08% to $17.0 million in 2023, then retreated by 20.36% to $13.5 million in 2024, then slipped by 8.89% to $12.3 million in 2025.
- The last three Common Equity figures came in at $12.3 million (Q4 2025), $11.2 million (Q3 2025), and $9.7 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Chemomab Therapeutics | 13.33 Mn | 2.96 Mn | - | 12.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 12.33 Mn |
| Sep 30, 2025 | 11.23 Mn |
| Jun 30, 2025 | 9.70 Mn |
| Mar 31, 2025 | 10.39 Mn |
| Dec 31, 2024 | 13.54 Mn |
| Sep 30, 2024 | 16.32 Mn |
| Jun 30, 2024 | 9.99 Mn |
| Mar 31, 2024 | 13.33 Mn |
| Dec 31, 2023 | 17.00 Mn |
| Sep 30, 2023 | 18.04 Mn |
| Jun 30, 2023 | 21.99 Mn |
| Mar 31, 2023 | 27.95 Mn |
| Dec 31, 2022 | 36.22 Mn |
| Sep 30, 2022 | 44.62 Mn |
| Jun 30, 2022 | 51.84 Mn |
| Mar 31, 2022 | 57.24 Mn |
| Dec 31, 2021 | 61.47 Mn |
| Sep 30, 2021 | 65.51 Mn |
| Jun 30, 2021 | 68.04 Mn |
| Mar 31, 2021 | 55.16 Mn |